Tuesday, October 13, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Take the Zacks Approach to Beat the Markets: Hershey's, Fastenal, Kennametal in Focus

View original at finance.yahoo.com
Take the Zacks Approach to Beat the Markets: Hershey's, Fastenal, Kennametal in Focus Last Friday, the three most widely followed benchmark indexes closed a mixed week…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to ECDP performance

    80% confidence

  • Optimism around economic resilience supported buying in cyclically sensitive and defensive sectors

    80% confidence

  • Rising Treasury yields and reduced confidence in near-term rate cuts made high-valuation growth stocks less attractive

    80% confidence

  • An equal-weight portfolio of Zacks Rank #1 stocks outperformed the equal-weight S&P 500 index by 7 percentage points

    80% confidence

  • ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
Take the Zacks Approach to Beat the Markets: Hershey's, Fastenal, Kennametal in Focus — Source | Via News | Via News